Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Financing In Brief

Executive Summary

Pfizer raises commercial bar with Toviaz YourWay program: Pfizer initiated its patient support program, YourWay, for its new overactive bladder treatment Toviaz (fesoterodine fumarate) as of June 2, the pharma announces. "We haven't done anything like this to date in the [OAB] category," Pfizer senior director of marketing Jim Maffezzoli, who oversees Toviaz, said in an interview. Pfizer launched Toviaz into an already-crowded OAB market in April, after FDA approval last fall (1"The Pink Sheet" DAILY, Nov. 3, 2008). The drug maker is positioning the YourWay plan as a means to improve patient compliance by supplementing treatment with information about diet, exercise, setting personal goals and the treatment itself; compliance is a major issue for OAB treatments. Studies are ongoing to evaluate the plan's impact, Pfizer said. Pfizer says payers already are responding to YourWay. Currently, Pfizer has an OAB awareness ad campaign on air with plans for branded direct-to-consumer advertising later this year. It is detailing the drug through its primary care business unit, which recently reorganized into a regional commercial model, which is similar, at least superficially, to steps taken by many of its peers

You may also be interested in...

Solvay Confirms It Is Looking At Options – But For All Of Its Businesses

In an interview, Solvay Pharma CEO says the company is “taking the offensive.”

Pfizer Toviaz Clears FDA For OAB: Three-Year Window To Establish Detrol Successor

Anti-muscarinic agent acquired from Schwarz in 2006 to hit U.S. market in 2009; in time to build sales before Pfizer’s Detrol goes off-patent in 2012.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts